Business
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS Canada NewsWire ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VANCOUVER, BC\n \n \n ,\n \n \n May 12, 2022\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants,  has released its financial and operating results for the three months ended\n \n March 31, 2022\n \n , reporting significant progress to its operational platform and strong liquidity.\n \n \n \n \n \n \n \n \n \n \"The first quarter this year saw us make progress on the safety and effectiveness of Willow's FutureGrown™ CBG as a key new ingredient for skincare\", said\n \n Trevor Peters\n \n , Willow's President and Chief Executive Officer. \"We are also excited to add new manufacturing capacity to further expand our end-to-end capabilities as a complete biomanufacturng solution for prospective partners. These are challenging times in the broader markets and at Willow we want to reitertate our strong balance sheet and world class R&D team that is set up to capture value for our stakeholders in the coming biorevolution.\"\n \n \n Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended\n \n March 31, 2022\n \n are available on SEDAR at\n \n www.sedar.com\n \n .\n \n \n \n Highlights for the Quarter\n \n \n \n \n On\n \n January 13, 2022\n \n , Willow announced the results of its in vitro analysis and was the first company to report on a topical clinical study on cannabigerol (\"\n \n CBG\n \n \"). In collaboration with Signum Biosciences, Willow's FutureGrown\n \n TM\n \n CBG, produced using its proprietary yeast platform at multi-kilogram scale, demonstrated antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays, and provided similar benefits when applied topically to huma...